FULL TEXT LINKS

Review Neurosurg Rev. 2024 Aug 27;47(1):484. doi: 10.1007/s10143-024-02738-w.

Circulating biomarkers literature in glioma patient populations

Donald Detchou ¹, Umaru Barrie ²

Affiliations

PMID: 39187709 DOI: 10.1007/s10143-024-02738-w

Abstract

Liquid biopsy, the process of identifying circulating biomarkers in patients with cancer, has emerged as clinically significant in population screening, tumor status & subclassification, and individualized patient treatment from tumor genotyping. While advances in genome sequencing and mass spectrometry have yielded large datasets available for mining and identified promising biomarkers in breast, melanoma, and lung cancers, among others, challenges persist in identifying biomarkers in neuro-oncology. Despite growing efforts in biomarker research and promise in their emergent clinical potential, there presently exists no validated circulating biomarker test for patients presenting with gliomas, the most common primary brain cancer.

Keywords: Biomarkers; Cell-free DNA; Circulating Tumor cells; Exosomes; MicroRNA; Proteomics.

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PubMed Disclaimer

1 di 1 05/09/2024, 09:37